Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)
China flag China · Delayed Price · Currency is CNY
9.60
-0.12 (-1.23%)
At close: Feb 13, 2026

SHA:603229 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
750.9795.07814.85764.23568.89405.1
Other Revenue
0.220.221.920.320.814.15
751.12795.29816.77764.55569.7409.25
Revenue Growth (YoY)
-10.07%-2.63%6.83%34.20%39.21%32.91%
Cost of Revenue
361.36373.39372.41372.58261.29182.58
Gross Profit
389.76421.9444.36391.96308.41226.67
Selling, General & Admin
116.84123.21118.41114.5581.2563.71
Research & Development
118.02100.4278.0667.0768.8250.77
Other Operating Expenses
15.536.543.321.974.644.05
Operating Expenses
248.39236.19199.81186.76156.21117.78
Operating Income
141.38185.71244.54205.2152.2108.89
Interest Expense
-7.74-7.76-7.99-6.11-1.47-1.38
Interest & Investment Income
47.7143.0835.759.65.788.23
Currency Exchange Gain (Loss)
11.411.411.3740.58-9.67-21.72
Other Non Operating Income (Expenses)
1.94-1.5-0.6-0.44-0.44-0.39
EBT Excluding Unusual Items
194.68230.92283.07248.84146.4193.63
Gain (Loss) on Sale of Investments
5.35.5-4.494.9511.66-5.23
Gain (Loss) on Sale of Assets
-----0.52-0.52
Asset Writedown
-0.19-0.15-0.37-1.58--
Other Unusual Items
12.473.9312.553.661.847.62
Pretax Income
212.27240.2290.76255.86159.3995.5
Income Tax Expense
27.4333.4136.8620.4813.468.66
Net Income
184.84206.79253.9235.38145.9386.84
Net Income to Common
184.84206.79253.9235.38145.9386.84
Net Income Growth
-28.23%-18.55%7.87%61.29%68.05%54.00%
Shares Outstanding (Basic)
835827819804794745
Shares Outstanding (Diluted)
835827819804794745
Shares Change (YoY)
3.53%0.99%1.92%1.16%6.67%0.25%
EPS (Basic)
0.220.250.310.290.180.12
EPS (Diluted)
0.220.250.310.290.180.12
EPS Growth
-30.68%-19.36%5.84%59.45%57.55%53.62%
Free Cash Flow
143.866.6258.38-151.35-136.9545.52
Free Cash Flow Per Share
0.170.080.07-0.19-0.170.06
Dividend Per Share
0.1000.1000.0920.0570.0370.023
Dividend Growth
8.58%8.58%61.30%53.91%62.72%39.88%
Gross Margin
51.89%53.05%54.40%51.27%54.14%55.39%
Operating Margin
18.82%23.35%29.94%26.84%26.72%26.61%
Profit Margin
24.61%26.00%31.09%30.79%25.61%21.22%
Free Cash Flow Margin
19.14%8.38%7.15%-19.80%-24.04%11.12%
EBITDA
220.36248.24285.14239.68182.22134.32
EBITDA Margin
29.34%31.21%34.91%31.35%31.99%32.82%
D&A For EBITDA
78.9962.5340.5934.4830.0225.43
EBIT
141.38185.71244.54205.2152.2108.89
EBIT Margin
18.82%23.35%29.94%26.84%26.71%26.61%
Effective Tax Rate
12.92%13.91%12.68%8.01%8.45%9.07%
Revenue as Reported
751.12795.29816.77764.55569.7409.25
Source: S&P Global Market Intelligence. Standard template. Financial Sources.